Annual EBITDA
-$47.41 M
+$3.20 M+6.32%
31 December 2023
Summary:
Galera Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$47.41 million, with the most recent change of +$3.20 million (+6.32%) on 31 December 2023. During the last 3 years, it has risen by +$21.58 million (+31.28%). GRTX annual EBITDA is now -101.30% below its all-time high of -$23.55 million, reached on 31 December 2018.GRTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$4.06 M
+$314.00 K+7.18%
30 June 2024
Summary:
Galera Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$4.06 million, with the most recent change of +$314.00 thousand (+7.18%) on 30 June 2024. Over the past year, it has increased by +$8.92 million (+68.72%). GRTX quarterly EBITDA is now at all-time high.GRTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$26.07 M
+$12.24 M+31.95%
30 June 2024
Summary:
Galera Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$26.07 million, with the most recent change of +$12.24 million (+31.95%) on 30 June 2024. Over the past year, it has increased by +$29.58 million (+53.15%). GRTX TTM EBITDA is now -394.61% below its all-time high of -$5.27 million, reached on 30 September 2018.GRTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GRTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.3% | +68.7% | +53.1% |
| 3 y3 years | +31.3% | +79.9% | +66.3% |
| 5 y5 years | -101.3% | +67.2% | +37.0% |
GRTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +34.7% | at high | +79.9% | at high | +66.3% |
| 5 y | 5 years | -101.3% | +34.7% | at high | +80.7% | at high | +66.3% |
| alltime | all time | -101.3% | +34.7% | at high | +80.7% | -394.6% | +66.3% |
Galera Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$4.06 M(-7.2%) | -$26.07 M(-32.0%) |
| Mar 2024 | - | -$4.37 M(-6.3%) | -$38.31 M(-19.2%) |
| Dec 2023 | -$47.41 M(-6.3%) | -$4.67 M(-64.0%) | -$47.41 M(-14.8%) |
| Sept 2023 | - | -$12.97 M(-20.4%) | -$55.65 M(+0.4%) |
| June 2023 | - | -$16.30 M(+21.0%) | -$55.44 M(+8.8%) |
| Mar 2023 | - | -$13.47 M(+4.3%) | -$50.97 M(+0.7%) |
| Dec 2022 | -$50.61 M(-30.3%) | -$12.91 M(+1.2%) | -$50.61 M(-2.2%) |
| Sept 2022 | - | -$12.76 M(+7.9%) | -$51.73 M(-12.6%) |
| June 2022 | - | -$11.83 M(-9.8%) | -$59.16 M(-13.4%) |
| Mar 2022 | - | -$13.11 M(-6.6%) | -$68.31 M(-5.9%) |
| Dec 2021 | -$72.56 M | -$14.03 M(-30.5%) | -$72.56 M(-6.1%) |
| Sept 2021 | - | -$20.19 M(-3.8%) | -$77.26 M(+6.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$20.98 M(+20.9%) | -$72.81 M(+5.4%) |
| Mar 2021 | - | -$17.36 M(-7.3%) | -$69.10 M(+0.2%) |
| Dec 2020 | -$68.99 M(+41.8%) | -$18.73 M(+19.0%) | -$68.99 M(+4.7%) |
| Sept 2020 | - | -$15.75 M(-8.8%) | -$65.92 M(+5.4%) |
| June 2020 | - | -$17.27 M(+0.1%) | -$62.53 M(+11.6%) |
| Mar 2020 | - | -$17.24 M(+10.1%) | -$56.02 M(+15.2%) |
| Dec 2019 | -$48.64 M(+106.5%) | -$15.66 M(+26.8%) | -$48.64 M(+17.6%) |
| Sept 2019 | - | -$12.36 M(+14.9%) | -$41.36 M(+20.7%) |
| June 2019 | - | -$10.76 M(+9.0%) | -$34.27 M(+45.7%) |
| Mar 2019 | - | -$9.86 M(+17.7%) | -$23.52 M(+72.2%) |
| Dec 2018 | -$23.55 M(-1.1%) | -$8.38 M(+59.1%) | -$13.65 M(+159.1%) |
| Sept 2018 | - | -$5.27 M | -$5.27 M |
| Dec 2017 | -$23.82 M | - | - |
FAQ
- What is Galera Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Galera Therapeutics?
- What is Galera Therapeutics annual EBITDA year-on-year change?
- What is Galera Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Galera Therapeutics?
- What is Galera Therapeutics quarterly EBITDA year-on-year change?
- What is Galera Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Galera Therapeutics?
- What is Galera Therapeutics TTM EBITDA year-on-year change?
What is Galera Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of GRTX is -$47.41 M
What is the all time high annual EBITDA for Galera Therapeutics?
Galera Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$23.55 M
What is Galera Therapeutics annual EBITDA year-on-year change?
Over the past year, GRTX annual earnings before interest, taxes, depreciation & amortization has changed by +$3.20 M (+6.32%)
What is Galera Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of GRTX is -$4.06 M
What is the all time high quarterly EBITDA for Galera Therapeutics?
Galera Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$4.06 M
What is Galera Therapeutics quarterly EBITDA year-on-year change?
Over the past year, GRTX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$8.92 M (+68.72%)
What is Galera Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of GRTX is -$26.07 M
What is the all time high TTM EBITDA for Galera Therapeutics?
Galera Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$5.27 M
What is Galera Therapeutics TTM EBITDA year-on-year change?
Over the past year, GRTX TTM earnings before interest, taxes, depreciation & amortization has changed by +$29.58 M (+53.15%)